Allogene's Blood Cancer Therapy Cuts Risk of Cancer Relapse in Mid ...

Allogene's blood cancer therapy cuts risk of cancer relapse in mid ...

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.

Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients

Allogene Therapeutics' off-the-shelf CAR-T treatment eliminated residual cancer cells in B-cell lymphoma patients three times better than standard care.

Off-the-Shelf CAR T Shows 58.3% MRD Clearance in Pretreated LBCL Group

At the day 45 MRD assessment, patients with large B-cell lymphoma treated with cema-cel saw a median decrease of 97.7% in their plasma ctDNA levels.

Allogene’s first look at data on its ‘off-the-shelf’ CAR-T shows promise

Allogene Therapeutics’ CAR-T therapy removed all remaining detectable lymphoma cells in just over half of treated patients, according to an early look at the Phase 2 data. The Bay Area biotech ...

Allogene CAR-T clears residual cancer better than standard

Off the shelf CAR T shows stronger residual clearance in lymphoma Allogene Therapeutics said its off the shelf CAR T therapy cleared residual cancer cells in patients with B cell lymphoma at a rate about three times higher than standard care. CAR T treatments use a patient’s immune cells that have…